DOLF

Assess the overall acceptability of the 3-drug treatment in the community as compared to the 2-drug treatment

Clinical Trial Triple Drug Study for LF

Assess the overall acceptability of the 3-drug treatment in the community as compared to the 2-drug treatment

Comparison of safety profile and acceptability between triple drug therapy (IVM,DEC,ALB) and standard two-drug therapy (DEC, ALB), plus STH evaluation.

To determine the frequency, type and severity of adverse events following triple-drug therapy (IVM+DEC+ALB, IDA) compared to the standard two-drug treatment (DEC+ALB, DA) in infected and uninfected individuals in a community.

To compare the efficacy of IDA vs. DA administered in communities for clearance of Mf and filarial antigenemia (Ag) in cohort and effectiveness (prevalence) in community settings. To assess the presence and intensity of filarial infection on the frequency and severity of adverse events. To compare community acceptance of MDA with IDA vs. DA.

Randomized clinical trail comparing treatment with Albendazole and Ivermectin to Ivermectin alone for Onchocerciasis.

Randomized Clinical Trial of Albendazole vs Ivermectin+Albendazole for lymphatic filariasis treatment and elimination.

Randomized Clinical Trial comparing triple triple therapy of DEC/Alb/Iver vs. DEC/Alb alone

Comparison of 2X vs. 1X per year MDA on Brugia with MDA of DEC/Alb , plus STH evaluation

Community MDA with 2X Alb alone for W. bancrofti in areas co-endemic for L. loa, plus STH evaluation